Highlights

  • MACH7 Technologies (ASX:M7T) reported Recurring Revenue of A$23.4 million in FY26, representing the majority of total revenue.
  • The company ended FY26 with A$19.9 million in cash and no debt.
  • Operating cash flow improved through the year, turning positive across three quarters.
  • Adoption of the Flamingo platform, customer retention and ARR growth are key areas to monitor.

MACH7 Technologies (ASX:M7T) is a healthcare software company focused on managing, integrating and delivering medical imaging data across healthcare systems.

The company experienced lower total revenue in FY26 due to reduced one-off Capital licensing revenue, but recurring revenue continued to represent the majority of its business.

The next phase will focus on whether its operational reset, new product platform and sales strategy can return the company to sustainable growth.

Latest Development

In its FY26 results released in late August 2026, MACH7 Technologies (ASX:M7T) reported revenue of A$27.9 million for the year ended 30 June 2026, down 17% from the prior year.

The decline was primarily driven by lower capital licence revenue, which fell 70% to A$1.5 million.

Recurring revenue reached A$23.4 million, representing 84% of total revenue, although it declined 8% year-on-year.

Annual recurring revenue was A$23.5 million at 30 June 2026, increasing 7.6% on a constant currency basis.

Adjusted EBITDA was negative A$0.9 million, while the net loss widened to A$8.9 million.

Company Overview

MACH7 Technologies (ASX:M7T) provides medical imaging data management software solutions for healthcare organisations.

Its platform integrates imaging systems with electronic health records and supports healthcare providers managing large volumes of diagnostic data.

The product suite includes:

  • Vendor Neutral Archive (VNA): A system for consolidating imaging data across on-premise, cloud and hybrid environments.
  • eUnity: A zero-footprint diagnostic viewer used by clinicians.
  • Flamingo: A newer orchestration platform designed to manage workflows involving artificial intelligence, teleradiology and research applications.

The majority of MACH7's operations are in North America, while financial reporting is conducted in Australian dollars.

Recent Developments

FY26 represented a restructuring and repositioning period for MACH7 Technologies (ASX:M7T).

Operating expenses declined 16% to A$26.7 million, excluding A$1.9 million in restructuring costs.

The company appointed new Leadership across technology, finance, commercial and legal functions and combined product and engineering teams.

During the year, MACH7 disclosed the loss of two major customers, Trinity Health and the Veterans Health Administration.

Despite this, FY26 sales orders totalled A$23.5 million in total contract value.

Approximately 86% of these orders were ARR-type contracts, while 21% came from new customers.

Forty percent of annual orders were secured during the fourth quarter, and the first Flamingo deployment was delivered to a new customer.

Financial and Operational Position

MACH7 Technologies (ASX:M7T) ended FY26 with cash of A$19.9 million and no debt.

Gross Margin remained high at 93%, while recurring revenue covered approximately 88% of operating expenses.

Quarterly Operating Cash Flow improved throughout FY26:

  • First quarter: negative A$3.7 million.
  • Second quarter: positive A$0.05 million.
  • Third quarter: positive A$1.2 million.
  • Fourth quarter: positive A$1.1 million.

The company also reported improving customer satisfaction metrics.

KLAS satisfaction scores for eUnity were 86.6 compared with a segment average of 83.1, while VNA scores improved to 73.6 from 68.7.

What Investors May Watch Next

The launch and adoption of Flamingo will be a major focus for MACH7 Technologies (ASX:M7T).

The platform is scheduled to launch at RSNA 2026 and includes a paid unified worklist module.

Management has identified four FY27 priorities:

  • ARR growth.
  • New customer wins.
  • Flamingo module adoption.
  • Continued Operating Expense discipline.

The company has not provided revenue or Earnings guidance.

Investors may therefore monitor quarterly ARR trends, order momentum, customer retention and whether fourth-quarter sales activity continues into FY27.

Risks

MACH7 Technologies (ASX:M7T) remains exposed to customer concentration risk, with the loss of two major customers demonstrating the potential impact of enterprise contract changes.

Total revenue declined despite growth in ARR, reflecting the transition away from capital licence revenue.

The commercial success of Flamingo remains unproven, and converting early deployments into broader adoption will be important.

Enterprise healthcare software is also a competitive market, with larger technology providers competing for healthcare system contracts.

Key Takeaways

MACH7 Technologies (ASX:M7T) enters FY27 following a year of restructuring rather than headline financial growth.

The company maintains several positive foundations, including high gross margins, significant recurring revenue, a debt-free Balance Sheet and improving cash flow trends.

The next stage will depend on whether the refreshed organisation, new Flamingo platform and sales initiatives can translate this foundation into renewed revenue growth.